Identification of female-specific risk enhancers throughout the lifespan of women to improve cardiovascular disease prevention
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Cardiovascular disease (CVD) remains the leading cause of death in women in the United States and globally, with heart disease actually on the rise among middle-aged women in the United States. This disease burden can be reduced by prioritizing a preventive approach to cardiovascular health. The 2019 American College of Cardiology (ACC)/American Heart Association (AHA) Guideline on the Primary Prevention of CVD contains important updates for delivery of primary prevention and also highlights early menopause and pre-eclampsia as two female-specific risk factors that enhance CVD risk. Additionally other female-specific risk factors including early menarche, polycystic ovarian syndrome, multi-parity, other adverse pregnancy outcomes, and hormone therapy also influence women's CVD risk throughout their lifespan. It is vital that both women and healthcare clinicians are made aware of this information as it has lifesaving potential. This review aims to (1) Introduce the key points of the 2019 ACC/AHA Guideline (2) Highlight the evidence for the female-specific risk factors for refining CVD risk assessment and (3) Discuss the impact of the female-specific risk enhancing factors on primary prevention interventions such as statin therapy. This approach will be able to more personalize risk assessment in women, with an emphasis on the importance of shared decision making in building authentic partnerships between clinicians and women patients throughout their lifespan.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175 · cited 1×
“Since that time, much initial progress was made, with steep declines in CVD deaths in women after the year 2000, in part driven by intensive women-specific preventive efforts and awareness campaigns [1].”
BackgroundArnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000678 · Cited by 4,536
Self-citation(2019) · doi:10.1161/cir.0000000000000677 · Cited by 4,501
Self-citationType 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis
Bellamy, L., Casas, J.-P., Hingorani, A. D., & Williams, D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60731-5 · Cited by 3,253 · cited 5×
“If a woman develops gestational diabetes, she has an 8-fold increased risk of acquiring T2DM [71].”
BackgroundInfluentialMosca, L., Benjamin, E. J., Berra, K., Bezanson, J. L., Dolor, R. J., Lloyd-Jones, D. M., Newby, L. K., Piña, I. L., Roger, V. L., Shaw, L. J., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820faaf8 · Cited by 2,143 · cited 1×
“Some of these efforts include the American Heart Association (AHA)’s Go Red for Women campaign and the publication of women-specific guidelines for CVD prevention by the AHA, first in 1999 and last updated in 2011 [2].”
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause
Rossouw, J. E., Prentice, R. L., Manson, J. E., Wu, L., Barad, D., Barnabei, V. M., Ko, M., LaCroix, A. Z., Margolis, K. L., & Stefanick, M. L. (2007) · JAMA · doi:10.1001/jama.297.13.1465 · Cited by 1,741 · cited 2×
“preventive benefit of MHT if given later in menopause is significantly reduced and may even be harmful in this setting [93].”
BackgroundPreeclampsia and Future Cardiovascular Health: A Systematic Review and Meta-Analysis
Wu, P., Haththotuwa, R., Kwok, C. S., Babu, A., Kotronias, R. A., Rushton, C., Zaman, A., Fryer, A. A., Kadam, U., Chew-Graham, C. A., et al. (2017) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.003497 · Cited by 1,147 · cited 3×
“profile for CVD such as dyslipidemia, obesity, chronic hypertension and insulin resistance [56].”
BackgroundInfluentialKramer, C. K., Campbell, S., & Retnakaran, R. (2019) · Diabetologia · doi:10.1007/s00125-019-4840-2 · Cited by 965 · cited 2×
“3-fold increased risk of CVD in the first decade postpartum [70].”
BackgroundEstrogen Therapy and Coronary-Artery Calcification
Manson, J. E., Allison, M. A., Rossouw, J. E., Carr, J. J., Langer, R. D., Hsia, J., Kuller, L. H., Cochrane, B. B., Hunt, J. R., Ludlam, S. E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071513 · Cited by 711
Budoff, M. J., Young, R., Burke, G., Jeffrey Carr, J., Detrano, R. C., Folsom, A. R., Kronmal, R., Lima, J. A. C., Liu, K. J., McClelland, R. L., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy217 · Cited by 684
Self-citationSalpeter, S. R., Walsh, J. M. E., Ormiston, T. M., Greyber, E., Buckley, N. S., & Salpeter, E. E. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00545.x · Cited by 640 · cited 2×
“However, there was a caveat that while oral agents resulted in larger beneficial effects than transdermal agents, they can adversely affect C-reactive protein and protein C, which was not seen with transdermal agents [90].”
BackgroundThrombotic stroke and myocardial infarction with hormonal contraception
Lidegaard, Ø., Løkkegaard, E., Jensen, A., Skovlund, C. W., & Keiding, N. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1111840 · Cited by 607
Osibogun, O., Ogunmoroti, O., & Michos, E. D. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.08.010 · Cited by 423 · cited 1×
“Women with PCOS have been shown to have increased risk for CVD events [28]; although it is debated whether this is independent of the above CVD risk factors or not [25].”
BackgroundSelf-citationNanna, M. G., Wang, T. Y., Xiang, Q., Goldberg, A. C., Robinson, J. G., Roger, V. L., Virani, S. S., Wilson, P. W. F., Louie, M. J., Koren, A., et al. (2019) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.005562 · Cited by 313 · cited 1×
“Additionally, women are less likely to be treated with guideline-recommended therapy such as statins, and even when offered statins, women are more likely to decline or discontinue therapy [7].”
BackgroundCombined oral contraceptives: the risk of myocardial infarction and ischemic stroke
Roach, R. E. J., Helmerhorst, F. M., Lijfering, W. M., Stijnen, T., Algra, A., & Dekkers, O. M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011054.pub2 · Cited by 299 · cited 2×
“with regard to the OCP pill was the one containing levonorgestrel and 30 microgram of estrogen [30].”
BackgroundBradley, C. K., Wang, T. Y., Li, S., Robinson, J. G., Roger, V. L., Goldberg, A. C., Virani, S. S., Louie, M. J., Lee, L. V., Peterson, E. D., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011765 · Cited by 286 · cited 1×
“Women may be more likely to underestimate their CVD risk and over-estimate their risk for side effects [8], leading to”
BackgroundKalantaridou, S. N., Naka, K. K., Papanikolaou, E., Kazakos, N., Kravariti, M., Calis, K. A., Paraskevaidis, E. A., Sideris, D. A., Tsatsoulis, A., Chrousos, G. P., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0015 · Cited by 284
Wu, P., Gulati, M., Kwok, C. S., Wong, C. W., Narain, A., O'Brien, S., Chew‐Graham, C. A., Verma, G., Kadam, U. T., & Mamas, M. A. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007809 · Cited by 204 · cited 1×
“Studies and subsequent meta-analyses have demonstrated that the occurrence of a preterm delivery is associated with a 2-fold increased risk of future CVD events [66,67].”
BackgroundSelf-citationCardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome
Glintborg, D., Rubin, K. H., Nybo, M., Abrahamsen, B., & Andersen, M. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0680-5 · Cited by 200 · cited 1×
“Women with PCOS have been shown to have increased risk for CVD events [28]; although it is debated whether this is independent of the above CVD risk factors or not [25].”
BackgroundAdverse pregnancy outcomes and future maternal cardiovascular disease
Hauspurg, A., Ying, W., Hubel, C. A., Michos, E. D., & Ouyang, P. (2018) · Clinical Cardiology · doi:10.1002/clc.22887 · Cited by 179 · cited 1×
“A history of preeclampsia was highlighted as a CVD risk-enhancing factor in the 2019 ACC/AHA Prevention Guideline and other reviews [3,11,53,54].”
BackgroundSelf-citationKavousi, M., Desai, C. S., Ayers, C., Blumenthal, R. S., Budoff, M. J., Mahabadi, A.-A., Ikram, M. A., van der Lugt, A., Hofman, A., Erbel, R., et al. (2016) · JAMA · doi:10.1001/jama.2016.17020 · Cited by 141
Pregnancy Loss and Later Risk of Atherosclerotic Disease
Ranthe, M. F., Andersen, E. A. W., Wohlfahrt, J., Bundgaard, H., Melbye, M., & Boyd, H. A. (2013) · Circulation · doi:10.1161/circulationaha.112.000285 · Cited by 117 · cited 1×
“worsened in women who undergo multiple fertility cycles or those who have miscarriages [46,47].”
BackgroundHeida, K. Y., Velthuis, B. K., Oudijk, M. A., Reitsma, J. B., Bots, M. L., Franx, A., van Dunné, F. M., & on behalf of the Dutch Guideline Development Group on Cardiovascular Risk Management after Reproductive Disorders (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487314566758 · Cited by 100 · cited 1×
“Preterm delivery is an independent predictor of CVD [69].”
BackgroundShostrom, D. C. V., Sun, Y., Oleson, J. J., Snetselaar, L. G., & Bao, W. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00144 · Cited by 96
Cited by
Pregnancy and Reproductive Risk Factors for Cardiovascular Disease in Women
O’Kelly, A. C., Michos, E. D., Shufelt, C. L., Vermunt, J. V., Minissian, M. B., Quesada, O., Smith, G. N., Rich-Edwards, J. W., Garovic, V. D., El Khoudary, S. R., et al. (2022) · Circulation Research · doi:10.1161/circresaha.121.319895 · Cited by 328
Self-citation2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.11.016 · Cited by 304
Wong, N. D., Budoff, M. J., Ferdinand, K., Graham, I. M., Michos, E. D., Reddy, T., Shapiro, M. D., & Toth, P. P. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100335 · Cited by 302
Self-citationRoeters van Lennep, J. E., Tokgözoğlu, L. S., Badimon, L., Dumanski, S. M., Gulati, M., Hess, C. N., Holven, K. B., Kavousi, M., Kayıkçıoğlu, M., Lutgens, E., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad472 · Cited by 229
Self-citationWriting Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001423 · Cited by 122
Metadata
- Authors
- Elder, P., Sharma, G., Gulati, M., & Michos, E. D.
- Venue
- American Journal of Preventive Cardiology
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 2
- Pages
- 100028
- ISSN
- 2666-6677 (ISSN-L)
- OpenAlex
- W3034001633
- Cited by
- 87
- References
- 24
- FWCI
- 8.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.